Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$294.39 -5.0%	$304.18	$253.30 ▼ $346.85	$158.15B	0.53	2.72 million shs	5.25 million shs
CVS CVS Health	$63.54 -5.9%	$63.47	$43.56 ▼ $75.12	$80.11B	0.54	11.57 million shs	13.29 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
KDP Keurig Dr Pepper	$33.81 -5.1%	$33.05	$30.12 ▼ $38.28	$45.87B	0.62	9.74 million shs	16.13 million shs
MNST Monster Beverage	$57.08 -4.3%	$53.17	$43.32 ▼ $60.34	$55.55B	0.71	7.01 million shs	10.39 million shs
PFE Pfizer	$22.99 -5.4%	$25.87	$22.95 ▼ $31.54	$130.39B	0.61	39.46 million shs	79.83 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+1.36%	+1.33%	-0.75%	+18.62%	+12.91%
CVS CVS Health	-1.03%	-0.23%	+4.95%	+47.34%	-9.62%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
KDP Keurig Dr Pepper	+1.39%	+4.00%	+6.04%	+12.97%	+14.90%
MNST Monster Beverage	+0.49%	+1.83%	+8.81%	+13.86%	+6.61%
PFE Pfizer	-1.76%	-3.02%	-5.52%	-8.63%	-10.78%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.2967 of 5 stars	2.2	4.0	3.3	3.9	3.5	2.5	0.6
CVS CVS Health	4.961 of 5 stars	3.5	4.0	3.3	3.9	2.8	3.3	3.1
HZNP Horizon Therapeutics Public	1.0516 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9
KDP Keurig Dr Pepper	4.2016 of 5 stars	3.3	3.0	1.7	1.2	2.9	3.3	1.3
MNST Monster Beverage	3.2256 of 5 stars	2.2	4.0	0.0	0.0	3.6	2.5	1.3
PFE Pfizer	4.9669 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
SGEN Seagen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$314.04	6.68% Upside
CVS CVS Health	2.90	Moderate Buy	$70.41	10.81% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
KDP Keurig Dr Pepper	2.64	Moderate Buy	$38.38	13.53% Upside
MNST Monster Beverage	2.42	Hold	$56.11	-1.70% Downside
PFE Pfizer	2.63	Moderate Buy	$31.92	38.86% Upside
SGEN Seagen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	MNST Monster Beverage	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$60.00 ➝ $65.00
4/1/2025	KDP Keurig Dr Pepper	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$38.00 ➝ $40.00
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/21/2025	CVS CVS Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$72.00 ➝ $74.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
3/3/2025	MNST Monster Beverage	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral	$53.00 ➝ $57.00
2/28/2025	MNST Monster Beverage	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $64.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.73	$29.50 per share	9.98	$10.93 per share	26.93
CVS CVS Health	$372.81B	0.21	$8.87 per share	7.16	$60.06 per share	1.06
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
KDP Keurig Dr Pepper	$15.35B	2.99	$2.36 per share	14.31	$18.36 per share	1.84
MNST Monster Beverage	$7.49B	7.41	$1.83 per share	31.15	$7.91 per share	7.22
PFE Pfizer	$63.63B	2.05	$3.60 per share	6.38	$15.81 per share	1.45
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	38.99	13.76	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
CVS CVS Health	$4.61B	$3.66	17.36	9.39	0.98	1.24%	9.11%	2.71%	4/29/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
KDP Keurig Dr Pepper	$2.18B	$1.05	20.49	16.66	2.42	15.04%	10.45%	4.99%	4/24/2025 (Estimated)
MNST Monster Beverage	$1.63B	$1.49	36.59	31.19	2.28	21.66%	23.31%	18.48%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	16.31	7.59	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	AMGN Amgen	$4.18	N/A	N/A	N/A	$8.05 billion	N/A
5/1/2025	N/A	MNST Monster Beverage	$0.46	N/A	N/A	N/A	$1.97 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	KDP Keurig Dr Pepper	$0.38	N/A	N/A	N/A	$3.57 billion	N/A
2/27/2025	Q4 2024	MNST Monster Beverage	$0.40	$0.38	-$0.02	$0.28	$1.80 billion	$1.81 billion
2/25/2025	Q4 2024	KDP Keurig Dr Pepper	$0.57	$0.58	+$0.01	-$0.11	$4.01 billion	$4.07 billion
2/12/2025	Q4 2024	CVS CVS Health	$0.89	$1.19	+$0.30	$1.30	$96.90 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.23%	+8.53%	126.09%	14 Years
CVS CVS Health	$2.66	4.19%	+9.97%	72.68%	N/A
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
KDP Keurig Dr Pepper	$0.92	2.72%	+7.70%	87.62%	N/A
MNST Monster Beverage	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.48%	+2.50%	121.99%	16 Years
SGEN Seagen	N/A	N/A	N/A	N/A	N/A

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
3/20/2025	CVS CVS Health	quarterly	$0.6650	3.89%	4/22/2025	4/22/2025	5/1/2025
2/11/2025	KDP Keurig Dr Pepper	quarterly	$0.23	2.92%	3/28/2025	3/28/2025	4/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
CVS CVS Health	0.80	0.81	0.60
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
KDP Keurig Dr Pepper	0.50	0.53	0.36
MNST Monster Beverage	0.13	3.13	2.51
PFE Pfizer	0.63	1.00	0.73
SGEN Seagen	N/A	2.67	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
CVS CVS Health	80.66%
HZNP Horizon Therapeutics Public	80.37%
KDP Keurig Dr Pepper	93.99%
MNST Monster Beverage	72.36%
PFE Pfizer	68.36%
SGEN Seagen	84.26%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
CVS CVS Health	0.24%
HZNP Horizon Therapeutics Public	2.20%
KDP Keurig Dr Pepper	1.00%
MNST Monster Beverage	7.80%
PFE Pfizer	0.06%
SGEN Seagen	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
CVS CVS Health	300,000	1.26 billion	1.26 billion	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
KDP Keurig Dr Pepper	28,000	1.36 billion	1.34 billion	Optionable
MNST Monster Beverage	4,090	973.16 million	896.66 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable

KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Headlines

Recent News About These Companies

Trial win sets up new use for Astellas, Seagen's Padcev in bladder cancer

March 16, 2025 | pharmaphorum.com

Merck in "advanced talks" for $40bn Seagen bid; report

March 7, 2025 | pharmaphorum.com

Seagen posts breast cancer win ahead of Pfizer takeover

February 23, 2025 | pharmaphorum.com

Is Merck planning a $30bn-plus move for Seagen?

December 6, 2024 | pharmaphorum.com

Pfizer raises guidance as COVID franchise drives Q3 beat

October 30, 2024 | seekingalpha.com

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

October 30, 2024 | seekingalpha.com

Franklin Biotechnology Discovery C

October 5, 2024 | morningstar.com

Seagen wins Enhertu patent dispute with Daiichi Sankyo

July 20, 2024 | pharmaphorum.com

Pfizer: Turning The Corner (Rating Upgrade)

May 27, 2024 | seekingalpha.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

April 13, 2024 | wsj.com

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

April 2, 2024 | pharmaphorum.com

Ron Baron Portfolio Magic: Building Your Financial Future

March 20, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 13, 2024 | msn.com

Pfizer shutting down Seagen's $350M construction project in Everett

March 1, 2024 | bizjournals.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 24, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

February 23, 2024 | finance.yahoo.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 23, 2024 | msn.com

MRNA Feb 2024 67.000 put

February 22, 2024 | finance.yahoo.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 12, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Company Descriptions

Amgen NASDAQ:AMGN

$294.39 -15.46 (-4.99%)

Closing price 04:00 PM Eastern

Extended Trading

$291.78 -2.61 (-0.89%)

As of 07:40 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CVS Health NYSE:CVS

$63.54 -3.97 (-5.88%)

Closing price 03:59 PM Eastern

Extended Trading

$63.64 +0.10 (+0.16%)

As of 07:58 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Keurig Dr Pepper NASDAQ:KDP

$33.81 -1.82 (-5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$33.98 +0.17 (+0.50%)

As of 07:48 PM Eastern

Keurig Dr Pepper Inc. owns, manufactures, and distributors beverages and single serve brewing systems in the United States and internationally. It operates through three segments: U.S. Refreshment Beverages, U.S. Coffee, and International. The U.S. Refreshment Beverages segment manufactures and distributes branded concentrates, syrup, and finished beverages. Its U.S. Coffee segment offers finished goods relating to K-Cup pods, single serve brewers, specialty coffee, and ready to drink coffee products through Keurig.com website. The International segment provides sales in Canada, Mexico, the Caribbean, and other international markets from the manufacture and distribution of branded concentrates, syrup, and finished beverages; and sales in Canada from the manufacture and distribution of finished goods relating to the Company's single serve brewers, KCup pods, and other coffee products. It serves retailers, third-party bottlers and distributors, retail partners, hotel chains, office coffee distributors, and end-use consumers. The company offers its products under the Dr Pepper, Canada Dry, Green Mountain Coffee Roasters, Snapple, Mott's, The Original Donut Shop, Clamato, and Core Hydration brand name. Keurig Dr Pepper Inc. was founded in 1981 and is headquartered in Burlington, Massachusetts.

Monster Beverage NASDAQ:MNST

$57.08 -2.57 (-4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$56.55 -0.53 (-0.93%)

As of 07:56 PM Eastern

Monster Beverage Corporation, through its subsidiaries, engages in development, marketing, sale, and distribution of energy drink beverages and concentrates in the United States and internationally. The company operates through three segments: Monster Energy Drinks, Strategic Brands, Alcohol Brands, and Other. It offers carbonated non-carbonated energy drinks, ready-to-drink iced teas, lemonades, juice cocktails, single-serve juices and fruit beverages, ready-to-drink dairy and coffee drinks, energy drinks, sports drinks and single-serve still waters, and sodas that are considered natural, sparkling juices, and flavored sparkling beverages. The company sells its products to full service beverage bottlers/distributors, retail grocery and specialty chains, wholesalers, club stores, mass merchandisers, convenience chains, food service customers, value stores, e-commerce retailers, and the military; and concentrates and/or beverage bases to authorized bottling and canning operations. It provides its products under the Monster Energy, Monster Energy Ultra, Monster Rehab, Monster Energy Nitro, Java Monster, Punch Monster, Juice Monster, Muscle Monster, Espresso Monster, Monster Tour Water, Fury, Monster MAXX, Caffe Monster, Monster Hydro, Monster HydroSport Super Fuel, Monster Dragon Tea, Reign Total Body Fuel, and Reign Inferno Thermogenic Fuel, Reign Storm, Bang Energy, NOS, Full Throttle, Burn, Mother, Nalu, Ultra Energy, Play and Power Play (stylized), Relentless, BPM, BU, Gladiator, Samurai, Live+, Predator, and Fury brands. The company was formerly known as Hansen Natural Corporation and changed its name to Monster Beverage Corporation in January 2012. Monster Beverage Corporation was founded in 1985 and is headquartered in Corona, California.

Pfizer NYSE:PFE

$22.99 -1.30 (-5.35%)

Closing price 03:59 PM Eastern

Extended Trading

$22.94 -0.05 (-0.22%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Earnings

Compare Dividends

Latest KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KDP, MNST, PFE, SGEN, AMGN, HZNP, and CVS Company Descriptions

Amgen NASDAQ:AMGN

CVS Health NYSE:CVS

Horizon Therapeutics Public NASDAQ:HZNP

Keurig Dr Pepper NASDAQ:KDP

Monster Beverage NASDAQ:MNST

Pfizer NYSE:PFE

Seagen NASDAQ:SGEN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools